Mirella L Altoe1, Kevin Kalinsky2, Alessandro Marone1, Hyun K Kim1, Hua Guo3, Hanina Hibshoosh3, Mariella Tejada2, Katherine D Crew2,4, Melissa K Accordino2, Meghna S Trivedi2, Dawn L Hershman2,4, Andreas H Hielscher5. 1. Departments of Biomedical Engineering, New York University Tandon School of Engineering, Brooklyn, NY, 11201, USA. 2. Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, 10032,, USA. 3. Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, USA. 4. Department of Epidemiology, Columbia University Irving Medical Center, New York, NY, 10032, USA. 5. Departments of Biomedical Engineering, New York University Tandon School of Engineering, Brooklyn, NY, 11201, USA. ahh4614@nyu.edu.
Abstract
BACKGROUND: The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing breast in patients administered neoadjuvant chemotherapy (NAC) for breast cancer are associated with pathologic complete response (pCR). METHODS: In this retrospective evaluation of 105 patients with stage II-III breast cancer, oxy-hemoglobin (ctO2Hb) from the contralateral non-tumor-bearing breast was collected and analyzed at different time points during NAC. The earliest monitoring imaging time point was after 2-3 weeks receiving taxane. Longitudinal data were analyzed using linear mixed-effects modeling to evaluate the contralateral breast ctO2Hb changes across chemotherapy when corrected for pCR status, age, and BMI. RESULTS: Patients who achieved pCR to NAC had an overall decrease of 3.88 μM for ctO2Hb (95% CI, 1.39 to 6.37 μM), p = .004, after 2-3 weeks. On the other hand, non-pCR subjects had a non-significant mean reduction of 0.14 μM (95% CI, - 1.30 to 1.58 μM), p > .05. Mixed-effect model results indicated a statistically significant negative relationship of ctO2Hb levels with BMI and age. CONCLUSIONS: This study demonstrates that the contralateral normal breast tissue assessed by DOTBIS is modifiable after NAC, with changes associated with pCR after only 2-3 weeks of chemotherapy.
BACKGROUND: The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing breast in patients administered neoadjuvant chemotherapy (NAC) for breast cancer are associated with pathologic complete response (pCR). METHODS: In this retrospective evaluation of 105 patients with stage II-III breast cancer, oxy-hemoglobin (ctO2Hb) from the contralateral non-tumor-bearing breast was collected and analyzed at different time points during NAC. The earliest monitoring imaging time point was after 2-3 weeks receiving taxane. Longitudinal data were analyzed using linear mixed-effects modeling to evaluate the contralateral breast ctO2Hb changes across chemotherapy when corrected for pCR status, age, and BMI. RESULTS: Patients who achieved pCR to NAC had an overall decrease of 3.88 μM for ctO2Hb (95% CI, 1.39 to 6.37 μM), p = .004, after 2-3 weeks. On the other hand, non-pCR subjects had a non-significant mean reduction of 0.14 μM (95% CI, - 1.30 to 1.58 μM), p > .05. Mixed-effect model results indicated a statistically significant negative relationship of ctO2Hb levels with BMI and age. CONCLUSIONS: This study demonstrates that the contralateral normal breast tissue assessed by DOTBIS is modifiable after NAC, with changes associated with pCR after only 2-3 weeks of chemotherapy.
Authors: Norman F Boyd; Lisa J Martin; Limei Sun; Helen Guo; Anna Chiarelli; Greg Hislop; Martin Yaffe; Salomon Minkin Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-11 Impact factor: 4.254
Authors: Jacqueline E Gunther; Emerson A Lim; Hyun K Kim; Molly Flexman; Mirella Altoé; Jessica A Campbell; Hanina Hibshoosh; Katherine D Crew; Kevin Kalinsky; Dawn L Hershman; Andreas H Hielscher Journal: Radiology Date: 2018-02-12 Impact factor: 11.105
Authors: W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Yngve Bremnes; Giske Ursin; Nils Bjurstam; Sabina Rinaldi; Rudolf Kaaks; Inger T Gram Journal: Int J Cancer Date: 2007-12-01 Impact factor: 7.396
Authors: Evgeniya S Grigoryeva; Liubov A Tashireva; Vladimir V Alifanov; Olga E Savelieva; Sergey V Vtorushin; Marina V Zavyalova; Nadezhda V Cherdyntseva; Vladimir M Perelmuter Journal: Int J Mol Sci Date: 2022-08-22 Impact factor: 6.208